Latest Safety News

Core Lithium has repositioned its Finniss Lithium Project as a low-cost underground operation with a 20-year mine life, slashing operating costs by a third and boosting production capacity. The company is advancing strategic funding while unlocking flexibility through a key offtake agreement termination.

Neurizon Therapeutics has made significant strides in developing its lead ALS drug candidate NUZ-001, unveiling a new liquid formulation and submitting a key regulatory response to the FDA. Clinical and preclinical data bolster hopes for broader neurodegenerative applications.

dorsaVi has acquired exclusive global rights to advanced RRAM technology, promising major performance gains in its biomedical sensors, while securing key contracts and raising $2.44 million to fuel US market growth.

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.

BrainChip Holdings reported a solid June quarter with $13.5 million in cash, increased customer inflows, and a strategic decision to remain listed on the ASX. The company advanced multiple commercial collaborations and expanded its intellectual property portfolio, signaling confidence in its edge AI technology roadmap.

Avecho Biotechnology has ramped up recruitment in its pivotal Phase III insomnia trial and is advancing plans for regulatory approval and commercialization of its TPM®-enhanced CBD capsule, aiming to be the first over-the-counter CBD insomnia treatment in Australia.

Capricorn Metals reported a strong June quarter with Karlawinda gold production meeting FY25 guidance and announced it is now debt free and unhedged. Development at Mt Gibson and Karlawinda Expansion projects progresses, supported by record cash flow.

Nexus Minerals has reported a significant new gold discovery at its Wallbrook Gold Project, highlighted by strong drilling results at the Payns Prospect, while progressing permitting for the Crusader-Templar deposit and maintaining a solid cash position.

Noxopharm has initiated its HERACLES clinical trial for SOF-SKN, marking a key milestone for its Sofra platform, while deepening partnerships and actively seeking new funding to sustain development.

WA Kaolin Limited reports robust production growth and expanding sales, driven by new technical kaolin grades and strong forward orders for FY26.

IGO Limited reported a robust operational quarter with improved safety and solid production at Greenbushes and Nova, offset by challenges at its Kwinana lithium refinery and an expected asset impairment.

IGO Limited reported robust operational performance in Q4 FY25 with improved safety and higher production at Greenbushes and Nova, while facing significant impairment at its Kwinana lithium refinery.